Role of copper in tumour angiogenesis—clinical implications
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 18 (1) , 1-8
- https://doi.org/10.1016/j.jtemb.2004.02.004
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Copper‐lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammationThe Journal of Trace Elements in Experimental Medicine, 2003
- The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin‐8 productionInternational Journal of Cancer, 2002
- Hohenheim Consensus Workshop: CopperEuropean Journal of Clinical Nutrition, 2002
- The Hallmarks of CancerCell, 2000
- Inhibitory effect of zinc on human prostatic carcinoma cell growthThe Prostate, 1999
- Copper Chelation Inhibits Tumor Angiogenesis in the Experimental 9L Gliosarcoma ModelNeurosurgery, 1995
- Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumorsJournal of Neuro-Oncology, 1993
- Serum ceruloplasmin and copper levels in patients with primary brain tumorsJournal of Molecular Medicine, 1984
- Skeletal changes of copper deficiency in infants receiving prolonged total parenteral nutritionThe Journal of Pediatrics, 1978
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971